Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 20Carcinoma, Non-Small-Cell Lung 19Pancreatic Neoplasms 17Triple Negative Breast Neoplasms 16Neoplasm Metastasis 9Parkinson Disease 4, Autosomal Dominant Lewy Body 6Neoplasms 5Lung Neoplasms 4Carcinoma 4Neoplasms by Site 3Adenocarcinoma 3Pancreatic Diseases 2Ovarian Neoplasms 2Neoplasms by Histologic Type 2Fallopian Tube Neoplasms 2Endocrine System Diseases 2Endocrine Gland Neoplasms 2Digestive System Neoplasms 2Digestive System Diseases 2Carcinoma, Pancreatic Ductal 2Carcinoma, Ductal, Breast 2Vaccinia 1Thromboembolism 1Thoracic Neoplasms 1Squamous Non-Small Cell Lung Cancer 1Squamous Cell Carcinoma of Head and Neck 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Peritoneal Neoplasms 1Pancreatic cancer, adult 1

Interventions

Gemcitabine 3Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2napabucasin 1ganitumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Endocrine Gland Neoplasms × 130-nm albumin-bound paclitaxel × Clear all
NCT02993731 2023-11-15

CanStem111P

Sumitomo Pharma America, Inc.

Phase 3 Completed
1,134 enrolled 18 charts
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Diseases, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal

NCT01964430 2023-06-28

apact

Celgene

Phase 3 Completed
866 enrolled 21 charts
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Neoplasms, Neoplasms by Site, Pancreatic Diseases, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡